Contact
Subscribe

Categorie

Scientific Publications

Website_AACR

,

Evaluation of a new co-cultured microbiome ecosystem therapy candidate (MaaT034) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors

Download the poster
MaaT Pharma
March 19, 2024
Website_ASH

,

A Multicentre, Randomized, Double-Blinded, Phase 2b Study Evaluating The Efficacy And Safety Of MaaT033, an Oral, Pooled Microbiome Ecosystem Therapy In Patients Undergoing Allogenic Hematopoietic Cell Transplantation to Improve Overall Survival: the PHOEBUS trial

Download the poster
MaaT Pharma
November 13, 2023
Website_SITC

,

Robust Machine Learning (ML) approach for Screening Microbiome Ecosystem Therapies (MET) Drug Candidates in combination with Immune Checkpoint Inhibitors

Download the poster
MaaT Pharma
October 12, 2023
Website_SITC

,

Evaluation of a new co-cultured Microbiome Ecosystem Therapy candidate (MaaT03X) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors

Download the poster
MaaT Pharma
October 12, 2023
WEBSITE-ISCB-LOGO

,

Benchmarking of shotgun metagenomics analysis results obtained with state-of-the-art optimized pipelines on simulated gut microbiome samples

Download the poster
MaaT Pharma
July 25, 2023
Website_ASH

,

Restoration of gut microbiota diversity with oral pooled fecal microbiotherapy in acute myeloid leukemia patients after intensive chemotherapy: the phase 1b CIMON trial

Download the poster
MaaT Pharma
December 11, 2022
Website_IHMC

,

Pooled allogenic fecal microbiotherapy MaaT013 for the treatment of steroid-refractory gastrointestinal acute graft-versus-host disease: results from the phase IIa HERACLES study and expanded access program

Download the poster
MaaT Pharma
November 13, 2022
Capture d’écran 2021-10-01 110242

,

MaaT Pharma Announces Publication of Results from Completed Phase 1/2 ODYSSEE Clinical Trial in Nature Communications

The trial of the autologous microbial therapy, MaaT011, met its primary endpoints through demonstration of restored gut microbiota balance and…
MaaT Pharma
May 25, 2021
odysee-maat-pharma-2

,

MaaT Pharma annonce la publication dans Nature Communications des résultats de l’essai clinique ODYSSEE de phase 1/2.

L’essai de la thérapie autologue de restauration du microbiote, MaaT011, a atteint ses objectifs principaux en démontrant la restauration de…
MaaT Pharma
May 25, 2021

We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.

COMPANY

Ressources

Contact

Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.

SOCIÉTÉ

Ressources

Contact

Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.

SOCIÉTÉ

Ressources

Contact

© 2026 MaaT Pharma. La mission de MaaT Pharma est de restaurer la fonction du microbiote afin de traiter des maladies potentiellement mortelles.

X-twitter Linkedin